ASX News
Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals
HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
Market Cap $26.33B
!
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| RMD | ResMed up on bullish analyst notes after solid quarter | 20/08/25 | 0 | 137 | |||
|
|||||||
| RMD | Ann: 144 Report of proposed sale of securities | 19/08/25 | 1 | 257 | |||
|
|||||||
| RMD | Ann: Departure of Directors and Election of Directors | 19/08/25 | 0 | 129 | |||
|
|||||||
| RMD | Ann: Update - Dividend/Distribution - RMD | 18/08/25 | 0 | 183 | |||
|
|||||||
| RMD | Ann: Statement of changes in beneficial ownership of securities | 12/08/25 | 0 | 221 | |||
|
|||||||
| RMD | Ann: Resmed Form 10-K Annual Report | 11/08/25 | 1 | 614 | |||
|
|||||||
| RMD | Ann: 144 Report of proposed sale of securities | 08/08/25 | 0 | 190 | |||
|
|||||||
| RMD | Ann: Statement of changes in beneficial ownership of securities | 08/08/25 | 0 | 170 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
| View More | |||||
 (20min delay)
|
|||||
|
Last
$45.14 |
Change
0.510(1.14%) |
Mkt cap ! $26.33B | |||
| Open | High | Low | Value | Volume |
| $44.70 | $45.20 | $44.70 | $35.26M | 783.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 518 | $45.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $45.20 | 512 | 1 |
View Market Depth
| Last trade - 16.17pm 21/08/2025 (20 minute delay) ? |
| RMD (ASX) Chart |
